In Press Release

Vancouver, British Columbia – October 22, 2019 – NeutriSci International Inc. (“NeutriSci”) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) is pleased to provide a further update on its manufacturing partnership with Cryopharm Corporation (“Cryopharm”). Cryopharm will acquire the exclusive manufacturing and distribution rights for the Dablets™ and Zenstix™ line of products for the State of Nevada.

In addition to being manufactured by Cryopharm in California, Dablets™ and Zenstix™ will now also be produced in Nevada under license and partnership with Cryopharm. Cryopharm will handle all aspects of the manufacturing and distribution of Dablets™ and Zenstix™ line in Nevada.

Ryan Erving, COO of Marbl Corporation stated, “Due to the overwhelming response for what is clearly becoming an industry-disrupting product offering we decided to expand our partnership with NeutriSci and acquire the exclusive rights for Dablets and Zenstics in Nevada. This became an obvious next step from our operations in California.”

“We are pleased to announce this expanded partnership with Cryopharm. Cryopharm has the ability to rapidly bring product lines to market which coincides with our current mandate. NeutriSci is focused on driving revenue and acquiring shelf space,” said Glen Rehman, CEO, and President of NeutriSci”

On Behalf of the Board of Directors of

Investor Relations
Tel: (403) 264-6320

About NeutriSci International Inc.

NeutriSci specializes in the innovation, production, and formulation of nutraceutical products. Established in 2009, NeutriSci’s is building sustainable sales models with Convenience, Chain Drug, and Mass Market and Supermarket retailers for neuenergy®, the Company’s natural energy and focus supplement that has at its core, the beneficial effects of blueberries.

Neuenergy® contains a unique patented combination of blueberries (pterostilbene) and naturally derived caffeine, and is a revolutionary energy tab designed to deliver enhanced focus and mental clarity with no sugar, no calories and no crash associated with typical energy products. To find out more about neuenergy®, please visit

For more information, please visit:

About Cryopharm Corporation

Cryopharm is a developer, producer, and distributor of medical-grade, dose-controlled recreational cannabis products. Marbl Melts are an industry-first rapidly dissolving cannabis melt product infused with THC and/or CBD. For more information, please visit:

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward-looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

Recommended Posts
Contact Us

Send us a message and we'll get back to you as soon as possible.

Not readable? Change text. captcha txt

Start typing and press Enter to search